MedPacto Appoints Clinical Advisory Committee Members Including Greg Recolle, Former Moderna CEO
[Asia Economy Reporter Lee Gwan-joo] MedPacto announced on the 24th that it has appointed four members, including Greg Licollari, former head of the rare diseases division at Moderna, to its Clinical Advisory Board (CAB).
The Clinical Advisory Board will provide consultation on the clinical development, technology transfer, and commercialization strategies for new pipelines, including Bactosertib, currently under development by MedPacto, and soon-to-be-disclosed substances related to bone disease treatment.
The newly appointed advisory members include Dr. Greg Licollari, John Leterrier, Deputy Director of the Seidman Cancer Center at Cleveland Medical Center, Hyun Bae, Professor of Orthopedics at Cedars-Sinai Medical Center, and Isaac Kim, Chief of Urology at Yale School of Medicine.
Dr. Greg Licollari, currently serving as Chief Medical and Innovation Officer at the global clinical trial organization ICON plc, previously held positions as head of the rare diseases division at Moderna and President and Chief Medical Officer at Castle Creek Pharmaceuticals.
Hot Picks Today
"Samsung and Hynix Were Once for the Underachievers"... Hyundai Motor Employee's Lament
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- After Losing Her Only Daughter, a Mother in China Gave Birth to Twins at 60... Reinventing Life at 76
- Ukraine Launches Large-Scale Retaliatory Attack on Moscow, 4 Civilians Killed
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
A MedPacto official explained, "The CAB will provide expert knowledge regarding the company's subsequent pipeline development, clinical strategies, and technology transfer partnering."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
